MBX Biosciences is trading at $55.05 (8.3% down) as investors lock in gains following an extended multi-month rally.
- The pullback is driven by profit-taking, reports of insider selling, and valuation concerns rather than any new negative clinical or regulatory developments.
- Broader weakness across the biotech sector is acting as a significant overhang, contributing to the downward momentum.
- Shares are seeing additional pressure in after-hours trading as market sentiment turns more cautious following the recent surge.